Home › Compare › VCCBF vs ABBV
VCCBF yields 0.86% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, VCCBF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of VCCBF + ABBV for your $10,000?
V-cube, Inc. develops and provides visual communication services to enterprise customers. The company offers V-CUBE Meeting, a cloud-based Web conferencing service; V-CUBE Seminar, a Web seminar product for seminars, training, and information sessions; V-CUBE Sales, a web conferencing tool for online sales; V-CUBE Learning, a learning management system (LMS) that has incorporated the virtual online platform for training and learning purposes; and V-CUBE Voice, a teleconferencing service. It also provides Telecube, a soundproof smartphone box that can be installed anywhere and there are tables and chairs, and a PC inside that can be used for web conferencing; QUMU, a cloud-type video distribution management system; Agora for implementation of video calls and live distribution on iOS/Android applications and websites; EventIn, an online event platform; V-CUBE Collaboration, a web conferencing service to share video and audio, and PC desktop screens in real-time; and Realwear explosion-proof smart glass. In addition, the company offers hardware related to visual communication, such as web cameras, headsets, microphones with echo cancellers, large LCD displays, etc., as well as post-installation management services. V-cube, Inc. was founded in 1998 and is headquartered in Tokyo, Japan.
Full VCCBF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.